<DOC>
	<DOCNO>NCT00166127</DOCNO>
	<brief_summary>The purpose study protocol evaluate blood concentration levosimendan administer different dos clinically employ cardiopulmonary bypass cardiac manipulation pump surgery patient require drug inotropic support ( improved heart function ) associate hemodynamic variable ( vital sign ) . Levosimendan one first agents new class drug use treat heart failure work via unique mechanism call calcium sensitization , make heart beat efficiently . Levosimendan also unique effect blood vessel , well cause relaxation , important therapeutic approach heart failure therapy .</brief_summary>
	<brief_title>Study Blood Concentrations Physiologic Effects Levosimendan Given During Heart Surgery</brief_title>
	<detailed_description>This non-randomized trial , patient assign one three dose group follow cardiopulmonary bypass prior manipulation heart pump group . A total 30 patient enrol study , 20 off-pump 10 subject pump . Levosimendan approve Europe treatment decompensated heart failure . It improve cardiac function without increase energy demand . The subject 's enrollment end Day 7 day discharge , whichever come first .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>At least 21 year age Less 80 year age ASA Class IIIIV Scheduled elective cardiac surgery Signed informed consent History heart failure , and/or leave ventricular ejection fraction &lt; 50 % Emergency surgery Withdrawal consent Uncontrollable ventricular arrhythmia Obstructive cardiomyopathy Confirmed pregnancy test woman childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>heart failure</keyword>
	<keyword>cardiac surgery</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>